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C
ongenital diaphragmatic 
hernia (CDH), which occurs 
in one in 2,500 live births [1], 
is the most life-threatening cause of 
lung hypoplasia and is associated with 
high mortality, morbidity, cost, and 
suffering. The lungs are abnormally 
“stiff” in neonates with CDH [2], 
necessitating mechanical ventilation, 
often at high airway pressures, to 
prevent atelectasis and maximize the 
surface area available for gas exchange.
The cause of low lung compliance 
in CDH is multifactorial and may 
involve aberrant remodeling of lung 
structure and/or a primary surfactant 
deﬁ  ciency. In the sheep model of CDH, 
the compliance of liquid-ﬁ  lled lungs is 
reduced [3], indicating involvement of 
surfactant-independent mechanisms; 
liquid ﬁ  lling of the lungs eliminates 
surface tension forces generated by the 
alveolar air−liquid interface. Indeed, 
increased thickness of inter-airspace walls 
and/or excessive collagen deposition in 
lung parenchyma have been reported 
in CDH [4]. On the other hand, a 
primary surfactant deﬁ  ciency has been 
implicated as a cause of abnormal lung 
hysteresis (see Glossary) in neonates with 
CDH, although the role of surfactant 
deﬁ  ciency in CDH remains controversial.
Pulmonary surfactant is a 
phospholipid–protein complex 
synthesized and secreted exclusively by 
alveolar epithelial type II (AEII) cells 
that lowers surface-tension forces at the 
alveolar air−liquid interface, thereby 
increasing lung compliance. Of the 
four surfactant-associated proteins 
(SP-A, -B, -C, and -D), it is the two 
smaller hydrophobic proteins, SP-B 
and SP-C, that interact with alveolar 
phospholipids to prevent alveolar 
collapse at low lung volumes. SP-A and 
SP-D are centrally involved in the innate 
immunity of the lung. Mechanical 
ventilation with high levels of inspired 
oxygen can impair surfactant synthesis 
and function, and should therefore 
be considered when evaluating studies 
involving human CDH.
Why should a primary surfactant 
deﬁ  ciency in newborns with CDH be of 
serious concern, given the availability 
of prophylactic surfactant preparations 
that signiﬁ  cantly improve lung 
compliance, pulmonary blood ﬂ  ow, and 
gas exchange? Clinically, the question 
of whether infants with CDH should 
receive exogenous surfactant therapy 
is important because such therapy 
can transiently compromise these 
fragile infants with minimal respiratory 
reserve. Moreover, if human CDH 
is indeed associated with a primary 
surfactant deﬁ  ciency, we may opt for 
alternative treatment strategies (such as 
antenatal glucocorticoids or fetal lung 
gene therapy) to enhance endogenous 
surfactant production before birth.
Current Knowledge on Surfactant 
Status in CDH
Surfactant phospholipids in CDH. 
Data from human studies support 
the premise that production of 
phospholipids is normal in CDH. In 
human fetuses with CDH examined 
between 33 and 38 weeks, amniotic 
ﬂ  uid lecithin to sphingomyelin (L/S) 
ratios and phosphatidylglycerol (PG) 
levels were not different from that 
of historical control data [5]. In the 
newborn period, concentrations of 
phosphatidylcholine (PC) and PG, and 
L/S ratios in bronchoalveolar lavage 
ﬂ  uid, appear to be normal in CDH [6]. 
Moreover, surfactant PC synthesis and 
pool size do not appear to be altered by 
CDH, although turnover of PC is faster 
in CDH, possibly due to increased 
catabolism and/or recycling [7].
Surfactant-associated proteins 
in CDH. Of the few studies that 
have examined SP expression 
in CDH, data are available only 
for SP-A. Using semiquantitative 
immunohistochemistry, Asabe and 
colleagues demonstrated decreased 
SP-A expression in AEII cells in the 
lungs of infants with CDH obtained at 
autopsy within 5 d after birth [8]. In 
another immunohistochemical study, 
Minowa et al. demonstrated decreased 
alveolar SP-A expression in three 
infants with CDH, although the authors 
did not report on individual patient 
demographics and ventilator support 
[9]. The concentration of SP-A in 
tracheal aspirates of infants with CDH 
has been shown to be either unchanged 
[10] or reduced [11] by CDH.
A New Study
In a new autopsy study published in 
PLoS Medicine, Jacques Bourbon and 
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Linked Research Article
This Perspective discusses the 
following new study published in PLoS 
Medicine:
Boucherat O, Benachi A, Chailley-Heu 
B, Franco-Montoya ML, Elie C, et al. (2007) 
Surfactant maturation is not delayed 
in human fetuses with diaphragmatic 
hernia. PLoS Med 4(7): e237. doi:10.1371/
journal.pmed.0040237
In an autopsy study of human fetuses, 
Jacques Bourbon and colleagues report 
that pulmonary surfactant content is not 
decreased in congenital diaphragmatic 
hernia.PLoS Medicine  |  www.plosmedicine.org 1157
colleagues investigated surfactant 
content in human fetuses with CDH 
compared to age-matched fetuses 
with nonpulmonary diseases [12]. 
The primary purpose of their study 
was to determine whether the major 
components of surfactant, namely 
disaturated PC and SPs, are altered 
by CDH during the latter half of fetal 
development. A secondary aim was 
to evaluate lung expression of three 
glucocorticoid-regulated mediators 
involved in AEII cell maturation, 
namely keratinocyte growth factor, 
leptin, and neuregulin 1, isoform β1.
The study found that fetal lung 
disaturated PC concentration and SP 
expression were similar in normal 
fetuses and those with CDH, and 
increased with advancing gestational 
age. Whereas lung keratinocyte growth 
factor levels decreased with age in 
normal fetuses, levels did not change 
in fetuses with CDH. Leptin and 
neuregulin 1, isoform β1 were similar 
in normal fetuses and fetuses with CDH 
and increased age. Taken together, 
these data indicate that both surfactant 
content and molecular regulators of 
AEII cell maturation are essentially 
normal in human CDH.
The ﬁ  ndings of this new study have 
important clinical implications. If 
alveolar surfactant levels are normal 
in the immediate newborn with 
CDH, prophylactic administration of 
surfactant may not be of beneﬁ  t in 
treating such infants.
Strengths and Limitations of 
the Study
This new study has many strengths. First, 
this is the only longitudinal study to 
compare pulmonary surfactant content 
in human fetuses with C DH with 
age-matched controls. Irrespective of 
gestational age, there were no signiﬁ  cant 
differences between fetuses with CDH 
and normal fetuses, which provides 
convincing evidence that surfactant 
content is normal in CDH. Second, 
unlike in previous studies, the fetal 
lungs were not ventilated, so the results 
are unaffected by extraneous factors 
that can alter surfactant production, 
speciﬁ  cally aggressive mechanical 
ventilation with high levels of inspired 
oxygen. Moreover, none of the mothers 
received antenatal glucocorticoids, 
which would inﬂ  uence surfactant 
content. Third, the study examined 
expression of all four pulmonary SPs. To 
date there has been no information on 
lung levels of the SPs that are involved 
in lowering alveolar surface tension 
forces, namely SP-B and -C.
However, there are important 
caveats of the study. Levels of 
surfactant content measured from lung 
tissues may not reﬂ  ect that present 
within the airspaces, particularly if 
surfactant secretion is abnormal in 
CDH. In addition, data on pulmonary 
disaturated phosphatidylcholine 
levels were reported only up to 33 
wk of gestation. It is conceivable that 
disaturated phosphatidylcholine levels 
may differ between fetuses with CDH 
and normal fetuses closer to full term. 
These caveats should be considered 
when interpreting results from the 
current study. Finally, because of 
the small number of fetuses, the 
study cannot correlate the degree of 
pulmonary hypoplasia and surfactant 
content. There is a spectrum of 
pulmonary hypoplasia associated with 
CDH, and surfactant status may be 
different between fetuses with severe 
lung growth deﬁ  cits and those with 
milder forms of the disease.
Unanswered Research Questions
Knowledge of alveolar surfactant 
levels in the immediate newborn 
is required to determine if CDH is 
associated with a primary surfactant 
deﬁ  ciency. Such information may be 
difﬁ  cult to obtain, because 
institutional review boards are unlikely 
to approve bronchoalveolar lavage 
in the newborn with severe CDH. 
However, it may be possible to evaluate 
surfactant status in fetal lung ﬂ  uid that 
is suctioned from the airways during 
cesarean deliveries.  
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GLOSSARY 
Alveolar epithelial type II (AEII) cells: 
The alveolar epithelium is composed of 
two cell types. The cuboidal type II cells 
synthesize and secrete surfactant and are 
progenitor cells for the elongated type I 
cells through which gas exchange occurs.
Lecithin sphingomyelin (L/S) ratio: 
The phospholipids lecithin and 
sphingomyelin are produced by the fetal 
lung and are secreted into the amniotic 
ﬂ  uid. The relative concentration of these 
phospholipids is used to determine the 
biochemical maturity of the lung.
Lung hysteresis: The difference in 
the pressure-volume curve between 
inspiration and expiration.
Phosphatidylglycerol: A surfactant 
phospholipid, representing 5%–13% of 
all phospholipids.
Phosphatidylcholine: The most 
abundant species of phospholipids 
in lung surfactant, representing 
approximately 85% of the lipids in 
surfactant.